|

Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction

RECRUITINGSponsored by Chongqing Medical University
Actively Recruiting
SponsorChongqing Medical University
Started2020-09-20
Est. completion2024-06-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06379152

Summary

Factors influencing the prognosis of patients with heart failure with preserved ejection fraction (HFpEF) have been extensively studied. Previous studies have found that elevated serum total bilirubin levels are associated with cardiac death, heart failure readmission, and all-cause mortality in patients with chronic heart failure. However, the relationship between direct bilirubin and prognosis in patients with HFpEF is unclear.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adult aged ≥18 years old；
* Diagnosed with HFpEF.

Diagnostic criteria including:

1. left ventricular ejection fraction ≥ 50%;
2. with the symptoms and/or signs of heart failure;
3. Patients in sinus rhythm：BNP≥35pg/ml and/or NT-proBNP≥125pg/ml；Patients with atrial fibrillation：BNP≥105pg/ml and/or NT-proBNP≥365pg/ml.

Exclusion Criteria:

* LVEF less than 49% at any time

Conditions3

Heart DiseaseHeart Failure With Preserved Ejection FractionPrognathism

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.